ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/VEGF-inhibitor

Search results

target/VEGF-inhibitor
5 trial(s) found.
NCT04938817
NSW2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)
QLD4032 - Chermside - The Prince Charles Hospital (COMPLETED)
NCT04305054
QLD4215 - Southport - Tasman Oncology (COMPLETED)
NCT04164199
NCT03486873
NCT02861573
Filters
PD-1
100%
PD-1/PD-L1
100%
VEGF
100%
LAG3
80%
TIGIT
60%
PARP
60%
CTLA4
40%
ILT4
20%
ERBB2
20%
HPK1
20%
KIT
20%
OX40
20%
PDGFR
20%
RET
20%
VEGFR
20%
VEGFR1
20%
VEGFR2
20%
VEGFR3
20%
AR
20%
CYP17A1
20%
HIF2a
20%
androgen axis
20%




















 






























	
		
	

    

        

			ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

			
    
			
  • Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
    • 
			
			
  • Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
    • 
			
			
  • No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
    • 
			
			
  • External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.
    • 
			
			


			By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.
			
		

        

            
The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

            
            
Users are free to:

            
    
                
  • Share — copy and redistribute the data in any medium or format
    • 
                
  • Adapt — remix, transform, and build upon the data
    • 
                
  • Use the data for any purpose, including commercial use
    • 
            

            
            
Under the following terms:

            
    
                
  • Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
    • 
                
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
    • 
            

            
            
Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.